Shalby Ltd. AI Stock Analysis
Want to see IN:SHALBY full AI Analyst Report?
Shalby Ltd. (SHALBY) AI Stock Analysis
Shalby Ltd.
(NSE:SHALBY)
The score is primarily pressured by weakening financial quality—negative operating/free cash flow and higher leverage alongside margin compression—despite strong revenue growth. Technicals are also weak with the stock trading below major moving averages and negative MACD. Valuation remains demanding at ~43.7x earnings, offering limited margin of safety.
Shalby Ltd. (SHALBY) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 12.84B
- Dividend Yield
- ―
- Average Volume (3M)
- 5,356
- Price to Earnings (P/E)
- 33.1
- Beta (1Y)
- 1.01
- Revenue Growth
- 7.27%
- EPS Growth
- 774.36%
- Country
- India
- Employees
- 2,217
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Care Facilities
Shalby Ltd. Business Overview & Revenue Model
Company Description
Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic...
Shalby Ltd. Financial Statement Overview
Summary
Strong revenue growth is offset by weaker quality of earnings: margin compression, rising leverage (debt-to-equity increasing to ~0.59 by FY2026), and materially deteriorating cash generation with negative operating and free cash flow in FY2025–FY2026. These factors increase funding and execution risk despite the expanding top line.
Income Statement
58NeutralBalance Sheet
62PositiveCash Flow
34Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.04B | 11.41B | 10.87B | 9.34B | 8.05B | 6.99B |
| Gross Profit | 2.70B | 2.09B | 2.02B | 2.50B | 3.70B | 3.05B |
| EBITDA | 1.48B | 1.43B | 1.60B | 1.90B | 1.61B | 1.30B |
| Net Income | 392.06M | 373.89M | 62.22M | 840.77M | 677.01M | 541.25M |
Balance Sheet | ||||||
| Total Assets | 18.57B | 18.39B | 17.04B | 16.08B | 12.81B | 11.94B |
| Cash, Cash Equivalents and Short-Term Investments | 725.92M | 841.97M | 1.29B | 1.08B | 2.16B | 2.02B |
| Total Debt | 5.85B | 5.95B | 4.76B | 3.78B | 1.81B | 1.74B |
| Total Liabilities | 8.35B | 8.33B | 7.08B | 6.00B | 3.54B | 3.17B |
| Stockholders Equity | 10.22B | 10.05B | 9.92B | 10.00B | 9.28B | 8.76B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.82B | -1.03B | -275.11M | 492.90M | -564.77M |
| Operating Cash Flow | 0 | -333.59M | -313.01M | 195.96M | 677.73M | 189.17M |
| Investing Cash Flow | 0 | -990.00M | -433.53M | 380.73M | -610.59M | -602.82M |
| Financing Cash Flow | 0 | 1.19B | 822.58M | -1.51B | -500.24M | 904.59M |
Shalby Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SHALBY, the sentiment is Negative. The current price of 119.35 is below the 20-day moving average (MA) of 120.85, below the 50-day MA of 131.71, and below the 200-day MA of 153.46, indicating a bearish trend. The MACD of -2.68 indicates Negative momentum. The RSI at 40.35 is Neutral, neither overbought nor oversold. The STOCH value of 18.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SHALBY.
Shalby Ltd. Peers Comparison
Overall Rating
IN:MEDANTA69Neutral
IN:MAXHEALTH63Neutral
IN:APOLLOHOSP62Neutral
IN:FORTIS59Neutral
IN:ASTERDM55Neutral
IN:SHALBY46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | INR 387.91B | 62.41 | ― | 0.07% | 26.18% | 10.09% | |
| 63Neutral | INR 994.74B | 72.13 | ― | 0.20% | 15.17% | 1.63% | |
| 62Neutral | INR 1.27T | 56.56 | ― | 0.23% | 19.24% | 34.11% | |
| 59Neutral | INR 601.70B | 57.67 | ― | 0.13% | 17.50% | 2.40% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | INR 643.99B | 101.11 | ― | 0.55% | 50.47% | 10.73% | |
| 46Neutral | INR 13.07B | 33.14 | ― | ― | 7.27% | 774.36% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:SHALBY | Shalby Ltd. | 119.35 | -102.70 | -46.25% | |
| IN:APOLLOHOSP | Apollo Hospitals Enterprise Limited | 8811.00 | 1408.27 | 19.02% | |
| IN:ASTERDM | Aster DM Healthcare Ltd. | 730.10 | 65.20 | 9.81% | |
| IN:FORTIS | Fortis Healthcare Ltd. | 797.00 | -137.56 | -14.72% | |
| IN:MAXHEALTH | Max Healthcare Institute Ltd | 1022.00 | -143.93 | -12.34% | |
| IN:MEDANTA | Global Health Limited | 1434.80 | 222.43 | 18.35% |
Shalby Ltd. Corporate Events
Shalby Shares Audio Recording of Q2 FY27 Earnings Call
Shalby Limited shared the audio recording of its Q2 FY27 earnings conference call held on November 4, 2026. The disclosure enables investors and other stakeholders to access management’s earnings discussion while supporting the company’s regulatory c...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 29, 2026
